October 21, 2026Stocks·Bullish·regulatory approval
FDA approves BioCryst's ORLADEYO oral pellet formulation for prophylactic therapy
The FDA approved BioCryst Pharma's supplemental new drug application for use of the oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in adults and adolescents aged 12 years and older.
Detected & updated continuously · Source: Nebula
Story subjects
Food and Drug AdministrationBioCryst Pharmaceuticals, Inc.